IMpassion050

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Nov 1, 2018 → Oct 23, 2026

Cited window

Jun 17, 2021 → Oct 23, 2026

Retrieved

Oct 31, 2026

Title

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

Registry

NCT03726879

Study IDs

BO40747

Sponsor

Hoffmann-La Roche

Collaborators

Chugai Pharmaceutical

Design

Phase 3 · Interventional, randomized, parallel

Status

Completed

Enrollment

454 actual

Registered

2018-11-01

Start

2019-01-11 actual

Primary completion

2021-02-05 actual

Primary endpoint

Percentage of Participants With Pathological Complete Response (pCR) in the PD-L1-Positive Population (IC 1/2/3)

Interventions

8 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –1 cited commentary passage leaves a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Not yet captured in this edition: a question about substituting paclitaxel for an unclearly identified chemotherapy regimen.
• –Not yet captured in this edition: a question about paclitaxel substitution and its greater consideration when selecting the neoadjuvant chemotherapy backbone.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –83 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative sample of HCP opinion; no prevalence, consensus percentage or independent-HCP count can be inferred.
• –Trial-name-centered searches can miss discussion that does not name IMpassion050, and some relevant passages were not fully assessed. Absence of a view in this report is not evidence that it was never expressed.
• –Some chemotherapy-free-strategy questions, response-definition qualifications and immediate-adoption context are not available as assessed statements, so the report cannot fully reconstruct that exchange.
• –Audio and video versions of the a speaker–another speaker interview describe the same conversation. Reposts relay material but do not independently establish endorsement.
• –Some recorded comments cannot be assigned to a named speaker and remain attributed only to the episode or discussion.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The final long-term analyses were descriptive, with small event counts and sample size determined for pCR. Numerical overall or subgroup differences are not established survival benefits.
• –Early discontinuation limits interpretation of the planned perioperative strategy, but the primary publication states that the coprimary pCR assessment was unaffected.
• –Fatal adverse events must not all be labeled treatment-related. Phase-specific safety reassurance must not be generalized to the whole study.
• –Descriptions of other studies, including regimen names and treatment-duration interpretations, are preserved as attributed commentary rather than silently corrected or treated as IMpassion050 findings.
• –Reported Canadian access constraints and institutional shortage adaptations describe their source settings and times, not universal or current reimbursement and practice.
• –The report does not establish current approval or labeling status.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "IMpassion050" (NCT03726879), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "impassion050-03726879". If you cannot make requests, read https://www.erudio.com/reports/impassion050-nct03726879.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT03726879", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct03726879 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/impassion050-nct03726879.json
curl https://www.erudio.com/reports/impassion050-nct03726879.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "impassion050-03726879" })